Stock futures edged down as investors kept on eye on the multiple quarrels over government spending taking place on Capitol Hill. Last week, the drug maker said its pill intended to treat Covid-19 had succeeded in a key study. Shares of some vaccine makers were extending declines premarket after having dropped last week following the report on Merck’s pill. Barclays upgraded its rating of the stock and lifted its price target to $75 a share. The bank also nudged its price target up to $85 a share from $84.

Source: Wall Street Journal October 31, 2021 08:09 UTC